Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix and BAL2062 -- ...

Expands available market to include over 200 children’s hospitals in the United StatesLEXINGTON, Mass., Sept. 16, 2024 (GLOBE ...

Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority ...

Background: Invasive candidiasis is increasingly prevalent in premature infants and seriously ill children, and pediatric data on available antifungal therapies are lacking. Methods: We conducted ...

Moreover, children with invasive candidiasis present a significant burden to the U.S. healthcare system, with a mean increased hospital length of stay of 21 days and approximately $92,000 in ...

Invasive fungal infections (IFIs) represent a serious and often overlooked threat to human health. These systemic infections occur when fungi, typically present in the environment, establish ...

Moreover, children with invasive candidiasis present a significant burden to the U.S. healthcare system, with a mean increased hospital length of stay of 21 days and approximately $92,000 in excess ...

Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Aspergillosis.

Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix a ...

The present article reviews these aspects for invasive aspergillosis and invasive candidiasis, the two most common life-threatening fungal infections. Among immunosuppressed children, the impact ...